{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:01:39Z","timestamp":1781812899084,"version":"3.54.5"},"reference-count":194,"publisher":"SMW Supporting Association","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>Despite the globally rising incidence of melanoma, mortality rates have decreased by approximately 18% in Caucasian populations following the introduction of effective systemic treatments.\nThanks to new molecular insights, the management of cutaneous melanoma has undergone several transformations over the past decade. The existing guidelines were last updated in 2016 to provide evidence-based practical recommendations for melanoma specialists across Switzerland. Recent data on surgical, radiotherapeutic and mainly systemic treatment with the implementation of adjuvant and neoadjuvant treatments in the current melanoma management have made modifications of the treatment and follow-up recommendations necessary.<\/jats:p>","DOI":"10.57187\/s.4210","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:30:14Z","timestamp":1752751814000},"page":"4210","source":"Crossref","is-referenced-by-count":2,"title":["The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma"],"prefix":"10.57187","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-7575","authenticated-orcid":false,"given":"Johanna","family":"Mangana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-0055","authenticated-orcid":false,"given":"Berna C.","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mihic-Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-7194","authenticated-orcid":false,"given":"Marco","family":"Siano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-9660","authenticated-orcid":false,"given":"Yannis","family":"Metaxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Valeska","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lindenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-4432","authenticated-orcid":false,"given":"Radu","family":"Olariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-8514","authenticated-orcid":false,"given":"Roger","family":"Von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6446","authenticated-orcid":false,"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Schiappacase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-1349","authenticated-orcid":false,"given":"Cristina","family":"Mangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4926-6355","authenticated-orcid":false,"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36756","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"94484","doi-asserted-by":"crossref","unstructured":"Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012 Nov;167(5):1124\u201330. 10.1111\/j.1365-2133.2012.11125.x","DOI":"10.1111\/j.1365-2133.2012.11125.x"},{"key":"94485","doi-asserted-by":"crossref","unstructured":"Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly. 2016 Feb;146:w14279. 10.4414\/smw.2016.14279","DOI":"10.4414\/smw.2016.14279"},{"key":"94486","doi-asserted-by":"crossref","unstructured":"Oxman AD, Sackett DL, Guyatt GH; The Evidence-Based Medicine Working Group. Users\u2019 guides to the medical literature. I. How to get started. JAMA. 1993 Nov;270(17):2093\u20135. doi: https:\/\/doi.org\/10.1001\/jama.1993.03510170083036","DOI":"10.1001\/jama.1993.03510170083036"},{"key":"94487","doi-asserted-by":"crossref","unstructured":"McGovern VJ. The classification of melanoma and its relationship with prognosis. Pathology. 1970 Apr;2(2):85\u201398. 10.3109\/00313027009077330","DOI":"10.3109\/00313027009077330"},{"key":"94488","unstructured":"Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969 Mar;29(3):705\u201327."},{"key":"94489","unstructured":"WHO blue book: classification of skin tumours 5th edition."},{"key":"94490","doi-asserted-by":"crossref","unstructured":"Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015 Sep;47(9):996\u20131002. 10.1038\/ng.3361","DOI":"10.1038\/ng.3361"},{"key":"94491","doi-asserted-by":"crossref","unstructured":"Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003 Dec;95(24):1878\u201390. 10.1093\/jnci\/djg123","DOI":"10.1093\/jnci\/djg123"},{"key":"94492","doi-asserted-by":"crossref","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017 May;545(7653):175\u201380. 10.1038\/nature22071","DOI":"10.1038\/nature22071"},{"key":"94493","unstructured":"Mihic-Probst D, Perren A, Schmid S, Saremaslani P, Komminoth P, Heitz PU. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res. 2004;24(4):2415\u20138."},{"key":"94494","doi-asserted-by":"crossref","unstructured":"Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. JAMA Netw Open. 2023 Jan;6(1):e2250613. 10.1001\/jamanetworkopen.2022.50613","DOI":"10.1001\/jamanetworkopen.2022.50613"},{"key":"94495","doi-asserted-by":"crossref","unstructured":"Grob JJ, Bonerandi JJ. The \u2018ugly duckling\u2019 sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998 Jan;134(1):103\u20134. 10.1001\/archderm.134.1.103-a","DOI":"10.1001\/archderm.134.1.103-a"},{"key":"94496","doi-asserted-by":"crossref","unstructured":"Salerni G, Carrera C, Lovatto L, Mart\u00ed-Laborda RM, Isern G, Palou J, et al. Characterization of 1152 lesions excised over 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. J Am Acad Dermatol. 2012 Nov;67(5):836\u201345. 10.1016\/j.jaad.2012.01.028","DOI":"10.1016\/j.jaad.2012.01.028"},{"key":"94497","doi-asserted-by":"crossref","unstructured":"Zhang S, Wang Y, Zheng Q, Li J, Huang J, Long X. Artificial intelligence in melanoma: A systematic review. J Cosmet Dermatol. 2022 Nov;21(11):5993\u20136004. 10.1111\/jocd.15323","DOI":"10.1111\/jocd.15323"},{"key":"94498","doi-asserted-by":"crossref","unstructured":"Phillips M, Marsden H, Jaffe W, Matin RN, Wali GN, Greenhalgh J, et al. Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions. JAMA Netw Open. 2019 Oct;2(10):e1913436. 10.1001\/jamanetworkopen.2019.13436","DOI":"10.1001\/jamanetworkopen.2019.13436"},{"key":"94499","doi-asserted-by":"crossref","unstructured":"McLeod M, Choudhary S, Giannakakis G, Nouri K. Surgical treatments for lentigo maligna: a review. Dermatol Surg. 2011 Sep;37(9):1210\u201328. 10.1111\/j.1524-4725.2011.02042.x","DOI":"10.1111\/j.1524-4725.2011.02042.x"},{"key":"94500","doi-asserted-by":"crossref","unstructured":"Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015 Nov;373(20):1926\u201336. 10.1056\/NEJMoa1502583","DOI":"10.1056\/NEJMoa1502583"},{"key":"94501","doi-asserted-by":"crossref","unstructured":"Spaccarelli N, Drozdowski R, Peters MS, Grant-Kels JM. Dysplastic nevus part II: Dysplastic nevi: Molecular\/genetic profiles and management. J Am Acad Dermatol. 2023 Jan;88(1):13\u201320. 10.1016\/j.jaad.2022.05.071","DOI":"10.1016\/j.jaad.2022.05.071"},{"key":"94502","doi-asserted-by":"crossref","unstructured":"Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May;60(5):872\u20135. 10.1016\/j.jaad.2008.09.067","DOI":"10.1016\/j.jaad.2008.09.067"},{"key":"94503","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al.; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472\u201392. 10.3322\/caac.21409","DOI":"10.3322\/caac.21409"},{"key":"94504","doi-asserted-by":"crossref","unstructured":"K\u00f6tt J, Zimmermann N, Zell T, R\u00fcnger A, Heidrich I, Geidel G, et al. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy. Eur J Cancer. 2024 May;202:113989. 10.1016\/j.ejca.2024.113989","DOI":"10.1016\/j.ejca.2024.113989"},{"key":"94505","doi-asserted-by":"crossref","unstructured":"Riber-Hansen R, Sjoegren P, Hamilton-Dutoit SJ, Steiniche T. Extensive pathological analysis of selected melanoma sentinel lymph nodes: high metastasis detection rates at reduced workload. Ann Surg Oncol. 2008 May;15(5):1492\u2013501. 10.1245\/s10434-008-9847-8","DOI":"10.1245\/s10434-008-9847-8"},{"key":"94506","doi-asserted-by":"crossref","unstructured":"Cook MG, Massi D, Szumera-Cie\u0107kiewicz A, Van den Oord J, Blokx W, van Kempen LC, et al.; EORTC Melanoma Group. An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. Eur J Cancer. 2019 Jun;114:1\u20137. 10.1016\/j.ejca.2019.03.010","DOI":"10.1016\/j.ejca.2019.03.010"},{"key":"94507","doi-asserted-by":"crossref","unstructured":"Riber-Hansen R, Hamilton-Dutoit SJ, Steiniche T. Nodal distribution, stage migration due to diameter measurement and the prognostic significance of metastasis volume in melanoma sentinel lymph nodes: a validation study. APMIS. 2014 Oct;122(10):968\u201375. 10.1111\/apm.12240","DOI":"10.1111\/apm.12240"},{"key":"94508","doi-asserted-by":"crossref","unstructured":"Laeijendecker AE, El Sharouni MA, Stathonikos N, Spoto CP, van de Wiel BA, Eijken EJ, et al. The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes. J Clin Pathol. 2024 May;77(6):372\u20137. 10.1136\/jcp-2023-209354","DOI":"10.1136\/jcp-2023-209354"},{"key":"94509","doi-asserted-by":"crossref","unstructured":"Mihic-Probst D, Saremaslani P, Komminoth P, Heitz PU. Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus. Virchows Arch. 2003 Dec;443(6):745\u201351. 10.1007\/s00428-003-0897-9","DOI":"10.1007\/s00428-003-0897-9"},{"key":"94510","doi-asserted-by":"crossref","unstructured":"Broman KK, Richman J, Bhatia S. Evidence and implementation gaps in management of sentinel node-positive melanoma in the United States. Surgery. 2022 Jul;172(1):226\u201333. 10.1016\/j.surg.2021.12.025","DOI":"10.1016\/j.surg.2021.12.025"},{"key":"94511","doi-asserted-by":"crossref","unstructured":"Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al.; The Augsburg Consensus. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000 Jul;89(2):236\u201341. doi: https:\/\/doi.org\/10.1002\/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO;2-0","DOI":"10.1002\/1097-0142(20000715)89:2<236::AID-CNCR5>3.0.CO;2-0"},{"key":"94512","doi-asserted-by":"crossref","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al.; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014 Feb;370(7):599\u2013609. 10.1056\/NEJMoa1310460","DOI":"10.1056\/NEJMoa1310460"},{"key":"94513","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 Jun;376(23):2211\u201322. 10.1056\/NEJMoa1613210"},{"key":"94514","doi-asserted-by":"crossref","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al.; German Dermatologic Cooperative Oncology Group. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019 Nov;37(32):3000\u20138. 10.1200\/JCO.18.02306","DOI":"10.1200\/JCO.18.02306"},{"key":"94515","doi-asserted-by":"crossref","unstructured":"Hall BJ, Schmidt RL, Sharma RR, Layfield LJ. Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. Am J Clin Pathol. 2013 Nov;140(5):635\u201342. 10.1309\/AJCPWSDDHLLW40WI","DOI":"10.1309\/AJCPWSDDHLLW40WI"},{"key":"94516","doi-asserted-by":"crossref","unstructured":"Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al.; Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005 Sep;242(3):302\u201311. 10.1097\/01.sla.0000181092.50141.fa","DOI":"10.1097\/01.sla.0000181092.50141.fa"},{"key":"94517","doi-asserted-by":"crossref","unstructured":"Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov;31(11):1449\u201361. 10.1016\/j.annonc.2020.07.005","DOI":"10.1016\/j.annonc.2020.07.005"},{"key":"94518","doi-asserted-by":"crossref","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 Feb;19(2):181\u201393. 10.1016\/S1470-2045(18)30015-9","DOI":"10.1016\/S1470-2045(18)30015-9"},{"key":"94519","doi-asserted-by":"crossref","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018 Nov;24(11):1655\u201361. 10.1038\/s41591-018-0198-0","DOI":"10.1038\/s41591-018-0198-0"},{"key":"94520","doi-asserted-by":"crossref","unstructured":"Long GV, Saw RP, Lo S, Nieweg OE, Shannon KF, Gonzalez M, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019 Jul;20(7):961\u201371. 10.1016\/S1470-2045(19)30331-6","DOI":"10.1016\/S1470-2045(19)30331-6"},{"key":"94521","doi-asserted-by":"crossref","unstructured":"Liu J, Blake SJ, Yong MC, Harjunp\u00e4\u00e4 H, Ngiow SF, Takeda K, et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016 Dec;6(12):1382\u201399. 10.1158\/2159-8290.CD-16-0577","DOI":"10.1158\/2159-8290.CD-16-0577"},{"key":"94522","unstructured":"Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021 Feb;27(2):301\u20139. 10.1038\/s41591-020-01188-3"},{"key":"94523","doi-asserted-by":"crossref","unstructured":"Reijers IL, Menzies AM, van Akkooi AC, Versluis JM, van den Heuvel NM, Saw RP, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022 Jun;28(6):1178\u201388. 10.1038\/s41591-022-01851-x","DOI":"10.1038\/s41591-022-01851-x"},{"key":"94524","doi-asserted-by":"crossref","unstructured":"Amaria RN, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (vol 24, pg 1649, 2018) . Nat Med. 2018 Dec;24(12):1942\u20131942. 10.1038\/s41591-018-0252-y","DOI":"10.1038\/s41591-018-0247-8"},{"key":"94525","doi-asserted-by":"crossref","unstructured":"Patel SP, Othus M, Moon J, Tetzlaff M, Buchbinder EI, Sondak VK, et al. S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma . J Clin Oncol. 2021 May;39(15):TPS9585. 10.1200\/JCO.2021.39.15_suppl.TPS9585","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9585"},{"key":"94526","doi-asserted-by":"crossref","unstructured":"Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021 Oct;27(10):1789\u201396. 10.1038\/s41591-021-01510-7","DOI":"10.1038\/s41591-021-01510-7"},{"key":"94527","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024 Nov;391(18):1696\u2013708. 10.1056\/NEJMoa2402604"},{"key":"94528","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017 May;18(5):611\u201322. 10.1016\/S1470-2045(17)30231-0","DOI":"10.1016\/S1470-2045(17)30231-0"},{"key":"94529","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018 May;378(19):1789\u2013801. 10.1056\/NEJMoa1802357","DOI":"10.1056\/NEJMoa1802357"},{"key":"94530","doi-asserted-by":"crossref","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 Nov;377(19):1813\u201323. 10.1056\/NEJMoa1708539","DOI":"10.1056\/NEJMoa1708539"},{"key":"94531","doi-asserted-by":"crossref","unstructured":"Tarhini AA, Lee SJ, Hodi FS, Rao UN, Cohen GI, Hamid O, et al.; Phase III Study of Adjuvant Ipilimumab. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg\/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: north American Intergroup E1609. J Clin Oncol. 2020 Feb;38(6):567\u201375. 10.1200\/JCO.19.01381","DOI":"10.1200\/JCO.19.01381"},{"key":"94532","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al.; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 Nov;377(19):1824\u201335. 10.1056\/NEJMoa1709030"},{"key":"94533","doi-asserted-by":"crossref","unstructured":"Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, et al. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2023 Jan;41(3):517\u201327. 10.1200\/JCO.22.00533","DOI":"10.1200\/JCO.22.00533"},{"key":"94534","doi-asserted-by":"crossref","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022 Jul;170:256\u201384. 10.1016\/j.ejca.2022.04.018","DOI":"10.1016\/j.ejca.2022.04.018"},{"key":"94535","doi-asserted-by":"crossref","unstructured":"Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al.; Dermatologic Cooperative Oncology Group. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 May;395(10236):1558\u201368. 10.1016\/S0140-6736(20)30417-7","DOI":"10.1016\/S0140-6736(20)30417-7"},{"key":"94536","doi-asserted-by":"crossref","unstructured":"Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer. 2022 Sep;173:285\u201396. 10.1016\/j.ejca.2022.06.041","DOI":"10.1016\/j.ejca.2022.06.041"},{"key":"94537","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evid. 2022 Nov;1(11):EVIDoa2200214. doi: 10.1056\/EVIDoa2200214. Epub 2022 Sep 10. PMID: 38319852.","DOI":"10.1056\/EVIDoa2200214"},{"key":"94538","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial. Eur J Cancer. 2024 Nov;211:114327. 10.1016\/j.ejca.2024.114327","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"94539","doi-asserted-by":"crossref","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 Sep;383(12):1139\u201348. 10.1056\/NEJMoa2005493","DOI":"10.1056\/NEJMoa2005493"},{"key":"94540","doi-asserted-by":"crossref","unstructured":"Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 Nov;391(18):1709\u201320. 10.1056\/NEJMoa2404139","DOI":"10.1056\/NEJMoa2404139"},{"key":"94541","doi-asserted-by":"crossref","unstructured":"Satzger I, Leiter U, Gr\u00e4ger N, Keim U, Garbe C, Gutzmer R. Melanoma-specific survival in patients with positive sentinel lymph nodes: relevance of sentinel tumor burden. Eur J Cancer. 2019 Dec;123:83\u201391. 10.1016\/j.ejca.2019.07.004","DOI":"10.1016\/j.ejca.2019.07.004"},{"key":"94542","doi-asserted-by":"crossref","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al.; KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr;399(10336):1718\u201329. 10.1016\/S0140-6736(22)00562-1","DOI":"10.1016\/S0140-6736(22)00562-1"},{"key":"94543","doi-asserted-by":"crossref","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov;29(11):2835\u201343. 10.1038\/s41591-023-02583-2","DOI":"10.1038\/s41591-023-02583-2"},{"key":"94544","doi-asserted-by":"crossref","unstructured":"Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May;42(14):1619\u201324. 10.1200\/JCO.23.02355","DOI":"10.1200\/JCO.23.02355"},{"key":"94545","doi-asserted-by":"crossref","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb;403(10427):632\u201344. 10.1016\/S0140-6736(23)02268-7","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"94546","doi-asserted-by":"crossref","unstructured":"Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011 Oct;117(20):4740\u201306. 10.1002\/cncr.26111","DOI":"10.1002\/cncr.26111"},{"key":"94547","doi-asserted-by":"crossref","unstructured":"McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008 Jul;15(3):239\u201347. 10.1177\/107327480801500307","DOI":"10.1177\/107327480801500307"},{"key":"94548","doi-asserted-by":"crossref","unstructured":"Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, et al. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Ann Surg Oncol. 2020 Apr;27(4):1180\u20138. 10.1245\/s10434-019-08099-9","DOI":"10.1245\/s10434-019-08099-9"},{"key":"94549","doi-asserted-by":"crossref","unstructured":"Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002 Jun;146(6):1042\u20136. 10.1046\/j.1365-2133.2002.04750.x","DOI":"10.1046\/j.1365-2133.2002.04750.x"},{"key":"94550","doi-asserted-by":"crossref","unstructured":"Fogarty GB, Hong A, Scolyer RA, Lin E, Haydu L, Guitera P, et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br J Dermatol. 2014 Jan;170(1):52\u20138. 10.1111\/bjd.12611","DOI":"10.1111\/bjd.12611"},{"key":"94551","doi-asserted-by":"crossref","unstructured":"Hendrickx A, Cozzio A, Plasswilm L, Panje CM. Radiotherapy for lentigo maligna and lentigo maligna melanoma - a systematic review. Radiat Oncol. 2020 Jul;15(1):174. 10.1186\/s13014-020-01615-2","DOI":"10.1186\/s13014-020-01615-2"},{"key":"94552","doi-asserted-by":"crossref","unstructured":"Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol. 2012 Jul;67(1):60\u20138. 10.1016\/j.jaad.2011.06.029","DOI":"10.1016\/j.jaad.2011.06.029"},{"key":"94553","doi-asserted-by":"crossref","unstructured":"Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtner CM, Peter RU, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000 Sep;43(3):477\u201382. 10.1067\/mjd.2000.106241","DOI":"10.1067\/mjd.2000.106241"},{"key":"94554","doi-asserted-by":"crossref","unstructured":"S. N. L. Angela M Hong, Gerald B Fogarty, Jonathan Stretch, Wei Wang, Pablo Fernandez Penas, Richard CW Martin, Matthew C Foote, Hans Peter Soyer, Jeremy Ruben, Victoria Mar, Lilian Rocha, Christopher Wratten, Helena Collgros, Amanda Regio Pereira, Bruna Melhoranse Gouveia, Richard A Scolyer, Madeleine T King, Pascale Guitera, A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna., Journal of Clinical Oncology, vol. 42, Number 16_suppl, 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.9502"},{"key":"94555","doi-asserted-by":"crossref","unstructured":"Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1837\u20139. 10.1016\/0360-3016(85)90042-2","DOI":"10.1016\/0360-3016(85)90042-2"},{"key":"94556","doi-asserted-by":"crossref","unstructured":"Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):429\u201332. 10.1016\/0360-3016(91)90053-7","DOI":"10.1016\/0360-3016(91)90053-7"},{"key":"94557","doi-asserted-by":"crossref","unstructured":"Hughes TM, Williams GJ, Gyorki DE, Kelly JW, Stretch JR, Varey AH, et al. Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1290\u20138. 10.1111\/jdv.17154","DOI":"10.1111\/jdv.17154"},{"key":"94558","doi-asserted-by":"crossref","unstructured":"Rule WG, Allred JB, Pockaj BA, Markovic SN, DiCaudo DJ, Erickson LA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Med. 2016 Aug;5(8):1890\u20136. 10.1002\/cam4.783","DOI":"10.1002\/cam4.783"},{"key":"94559","doi-asserted-by":"crossref","unstructured":"Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014 May;120(9):1369\u201378. 10.1002\/cncr.28412","DOI":"10.1002\/cncr.28412"},{"key":"94560","doi-asserted-by":"crossref","unstructured":"Guadagnolo BA, Prieto V, Weber R, Ross MI, Zagars GK. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer. 2014 May;120(9):1361\u20138. 10.1002\/cncr.28415","DOI":"10.1002\/cncr.28415"},{"key":"94561","doi-asserted-by":"crossref","unstructured":"Oliver DE, Patel KR, Parker D, Delman KA, Lawson DH, Kudchadkar RR, et al. The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma Res. 2015 Apr;25(2):95\u2013102. 10.1097\/CMR.0000000000000139","DOI":"10.1097\/CMR.0000000000000139"},{"key":"94562","doi-asserted-by":"crossref","unstructured":"Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003 Jun;25(6):423\u20138. 10.1002\/hed.10263","DOI":"10.1002\/hed.10263"},{"key":"94563","doi-asserted-by":"crossref","unstructured":"Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial . Lancet Oncol. 2012 Jun;13(6):589\u201397. 10.1016\/S1470-2045(12)70138-9","DOI":"10.1016\/S1470-2045(12)70138-9"},{"key":"94564","doi-asserted-by":"crossref","unstructured":"Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009 Dec;115(24):5836\u201344. 10.1002\/cncr.24627","DOI":"10.1002\/cncr.24627"},{"key":"94565","doi-asserted-by":"crossref","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct;29 Suppl 4:iv166\u201391. 10.1093\/annonc\/mdy152","DOI":"10.1093\/annonc\/mdy152"},{"key":"94566","doi-asserted-by":"crossref","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4\u201312. 10.1016\/j.prro.2016.08.001","DOI":"10.1016\/j.prro.2016.08.001"},{"key":"94567","doi-asserted-by":"crossref","unstructured":"Harada H, Katagiri H, Kamata M, Yoshioka Y, Asakura H, Hashimoto T, et al. Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res. 2010;51(2):131\u20136. 10.1269\/jrr.09096","DOI":"10.1269\/jrr.09096"},{"key":"94568","doi-asserted-by":"crossref","unstructured":"Sprave T, Hees K, Bruckner T, Foerster R, Bostel T, Schlampp I, et al. The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol. 2018 Jul;13(1):134. 10.1186\/s13014-018-1082-2","DOI":"10.1186\/s13014-018-1082-2"},{"key":"94569","doi-asserted-by":"crossref","unstructured":"Sprave T, Verma V, F\u00f6rster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018 Oct;13(1):212. 10.1186\/s13014-018-1161-4","DOI":"10.1186\/s13014-018-1161-4"},{"key":"94570","doi-asserted-by":"crossref","unstructured":"Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial. J Clin Oncol. 2024 Jan;42(1):38\u201346. 10.1200\/JCO.23.00753","DOI":"10.1200\/JCO.23.00753"},{"key":"94571","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019 May;393(10185):2051\u20138. 10.1016\/S0140-6736(18)32487-5","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"94572","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep;38(25):2830\u20138. 10.1200\/JCO.20.00818","DOI":"10.1200\/JCO.20.00818"},{"key":"94573","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18\u201328. 10.1016\/S1470-2045(19)30718-1","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"94574","doi-asserted-by":"crossref","unstructured":"Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev. 2017 Feb;53:25\u201337. 10.1016\/j.ctrv.2016.11.013","DOI":"10.1016\/j.ctrv.2016.11.013"},{"key":"94575","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al.; CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025 Jan;392(1):11\u201322. 10.1056\/NEJMoa2407417"},{"key":"94576","doi-asserted-by":"crossref","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Dec;35(12):1191\u20139. 10.1016\/j.annonc.2024.08.2330","DOI":"10.1016\/j.annonc.2024.08.2330"},{"key":"94577","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al.; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan;386(1):24\u201334. 10.1056\/NEJMoa2109970","DOI":"10.1056\/NEJMoa2109970"},{"key":"94578","doi-asserted-by":"crossref","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun;372(26):2521\u201332. 10.1056\/NEJMoa1503093","DOI":"10.1056\/NEJMoa1503093"},{"key":"94579","doi-asserted-by":"crossref","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017 Mar;35(7):785\u201392. 10.1200\/JCO.2015.66.1389","DOI":"10.1200\/JCO.2015.66.1389"},{"key":"94580","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 Oct;377(14):1345\u201356. 10.1056\/NEJMoa1709684"},{"key":"94581","doi-asserted-by":"crossref","unstructured":"Lebb\u00e9 C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial. J Clin Oncol. 2019 Apr;37(11):867\u201375. 10.1200\/JCO.18.01998","DOI":"10.1200\/JCO.18.01998"},{"key":"94582","doi-asserted-by":"crossref","unstructured":"Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M, et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024 Feb;198:113476. 10.1016\/j.ejca.2023.113476","DOI":"10.1016\/j.ejca.2023.113476"},{"key":"94583","doi-asserted-by":"crossref","unstructured":"Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, et al. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 Apr;40(10):1068\u201380. 10.1200\/JCO.21.01701","DOI":"10.1200\/JCO.21.01701"},{"key":"94584","doi-asserted-by":"crossref","unstructured":"Pires da Silva I, Ahmed T, Reijers IL, Weppler AM, Betof Warner A, Patrinely JR, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 Jun;22(6):836\u201347. 10.1016\/S1470-2045(21)00097-8","DOI":"10.1016\/S1470-2045(21)00097-8"},{"key":"94585","doi-asserted-by":"crossref","unstructured":"Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, et al. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF\/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer. 2022 Jul;10(7):e004610. 10.1136\/jitc-2022-004610","DOI":"10.1136\/jitc-2022-004610"},{"key":"94586","doi-asserted-by":"crossref","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248\u201360. 10.1016\/S1470-2045(16)30122-X","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"94587","doi-asserted-by":"crossref","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603\u201315. 10.1016\/S1470-2045(18)30142-6","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"94588","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 Jan;41(2):186\u201397. 10.1200\/JCO.22.01763"},{"key":"94589","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. J Clin Oncol. 2023 Jan;41(2):212\u201321. 10.1200\/JCO.21.02961","DOI":"10.1200\/JCO.21.02961"},{"key":"94590","doi-asserted-by":"crossref","unstructured":"Dixon-Douglas JR, Patel RP, Somasundram PM, McArthur GA. Triplet Therapy in Melanoma - Combined BRAF\/MEK Inhibitors and Anti-PD-(L)1 Antibodies. Curr Oncol Rep. 2022 Aug;24(8):1071\u20139. 10.1007\/s11912-022-01243-x","DOI":"10.1007\/s11912-022-01243-x"},{"key":"94591","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023 Jan;24(1):33\u201344. 10.1016\/S1470-2045(22)00687-8","DOI":"10.1016\/S1470-2045(22)00687-8"},{"key":"94592","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, et al. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic\/unresectable BRAF V600-mutant melanoma. Future Oncol. 2022 Jun;18(17):2041\u201351. 10.2217\/fon-2021-1486","DOI":"10.2217\/fon-2021-1486"},{"key":"94593","doi-asserted-by":"crossref","unstructured":"Ribas A, Chesney J, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. \u2219\u22191037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL). Ann Oncol. 2021;32 suppl. 5:S868\u20139. doi: https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1422","DOI":"10.1016\/j.annonc.2021.08.1422"},{"key":"94594","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019 Feb;5(2):187\u201394. 10.1001\/jamaoncol.2018.4514","DOI":"10.1001\/jamaoncol.2018.4514"},{"key":"94595","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug;40(12):1825\u201336. doi: https:\/\/doi.org\/10.1016\/j.ejca.2004.04.030","DOI":"10.1016\/j.ejca.2004.04.030"},{"key":"94596","doi-asserted-by":"crossref","unstructured":"Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al.; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul;47(10):1476\u201383. 10.1016\/j.ejca.2011.04.030","DOI":"10.1016\/j.ejca.2011.04.030"},{"key":"94597","doi-asserted-by":"crossref","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000 Jan;18(1):158\u201366. 10.1200\/JCO.2000.18.1.158","DOI":"10.1200\/JCO.2000.18.1.158"},{"key":"94598","doi-asserted-by":"crossref","unstructured":"von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, et al.; Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50\/07). Ann Oncol. 2012 Feb;23(2):531\u20136. 10.1093\/annonc\/mdr126","DOI":"10.1093\/annonc\/mdr126"},{"key":"94599","doi-asserted-by":"crossref","unstructured":"Birck A, Kirkin AF, Zeuthen J, Hou-Jensen K. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res. 1999 Aug;9(4):375\u201381. 10.1097\/00008390-199908000-00006","DOI":"10.1097\/00008390-199908000-00006"},{"key":"94600","doi-asserted-by":"crossref","unstructured":"Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumour Angiogenesis Research Group. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway\u2014a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006 Sep;24(26):4301\u20138. 10.1200\/JCO.2006.05.9501","DOI":"10.1200\/JCO.2006.05.9501"},{"key":"94601","doi-asserted-by":"crossref","unstructured":"Petrelli F, Ardito R, Merelli B, Lonati V, Cabiddu M, Seghezzi S, et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res. 2019 Feb;29(1):1\u201312. 10.1097\/CMR.0000000000000520","DOI":"10.1097\/CMR.0000000000000520"},{"key":"94602","doi-asserted-by":"crossref","unstructured":"Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012 Jan;30(1):34\u201341. 10.1200\/JCO.2011.34.6270","DOI":"10.1200\/JCO.2011.34.6270"},{"key":"94603","doi-asserted-by":"crossref","unstructured":"Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2023 Jan;41(1):75\u201385. 10.1200\/JCO.22.00221","DOI":"10.1200\/JCO.22.00221"},{"key":"94604","doi-asserted-by":"crossref","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 Aug;39(24):2656\u201366. 10.1200\/JCO.21.00612","DOI":"10.1200\/JCO.21.00612"},{"key":"94605","doi-asserted-by":"crossref","unstructured":"Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases . J Cancer Res Ther. 2012;8(2):215\u201321. 10.4103\/0973-1482.98973","DOI":"10.4103\/0973-1482.98973"},{"key":"94606","doi-asserted-by":"crossref","unstructured":"Nieder C, Grosu AL, Gaspar LE. Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat Oncol. 2014 Jul;9(1):155. 10.1186\/1748-717X-9-155","DOI":"10.1186\/1748-717X-9-155"},{"key":"94607","doi-asserted-by":"crossref","unstructured":"Bates JE, Youn P, Usuki KY, Walter KA, Huggins CF, Okunieff P, et al. Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. J Neurooncol. 2015 Nov;125(2):411\u20138. 10.1007\/s11060-015-1932-9","DOI":"10.1007\/s11060-015-1932-9"},{"key":"94608","unstructured":"Rades D, Sehmisch L, Huttenlocher S, Blank O, Hornung D, Terheyden P, et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Res. 2014 Sep;34(9):5079\u201382."},{"key":"94609","doi-asserted-by":"crossref","unstructured":"Christ SM, Mahadevan A, Floyd SR, Lam FC, Chen CC, Wong ET, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma. Surg Neurol Int. 2015 Aug;6(13 Suppl 12):S355\u201365. 10.4103\/2152-7806.163315","DOI":"10.4103\/2152-7806.163315"},{"key":"94610","doi-asserted-by":"crossref","unstructured":"DiLuna ML, King JT Jr, Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases . Cancer. 2007 Jan;109(1):135\u201345. 10.1002\/cncr.22367","DOI":"10.1002\/cncr.22367"},{"key":"94611","doi-asserted-by":"crossref","unstructured":"Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article . J Neurosurg. 2011 Mar;114(3):769\u201379. 10.3171\/2010.5.Jns1014 doi: https:\/\/doi.org\/10.3171\/2010.5.JNS1014","DOI":"10.3171\/2010.5.JNS1014"},{"key":"94612","doi-asserted-by":"crossref","unstructured":"Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases . Neurosurgery. 2007 Mar;60(3):471\u201381. 10.1227\/01.Neu.0000255342.10780.52 doi: https:\/\/doi.org\/10.1227\/01.NEU.0000255342.10780.52","DOI":"10.1227\/01.NEU.0000255342.10780.52"},{"key":"94613","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study . Lancet Oncol. 2014 Apr;15(4):387\u201395. 10.1016\/S1470-2045(14)70061-0","DOI":"10.1016\/S1470-2045(14)70221-9"},{"key":"94614","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Serizawa T, Sato Y, Higuchi Y, Kasuya H. Stereotactic Radiosurgery Results for Patients with 5-10 versus 11-20 Brain Metastases: A Retrospective Cohort Study Combining 2 Databases Totaling 2319 Patients . World Neurosurg. 2021 Feb;146:e479\u201391. 10.1016\/j.wneu.2020.10.124","DOI":"10.1016\/j.wneu.2020.10.124"},{"key":"94615","doi-asserted-by":"crossref","unstructured":"Chen WC, Baal UH, Baal JD, Pai JS, Boreta L, Braunstein SE, et al. Efficacy and Safety of Stereotactic Radiosurgery for Brainstem Metastases: A Systematic Review and Meta-analysis . JAMA Oncol. 2021 Jul;7(7):1033\u201340. 10.1001\/jamaoncol.2021.1262","DOI":"10.1001\/jamaoncol.2021.1262"},{"key":"94616","doi-asserted-by":"crossref","unstructured":"Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases . Int J Radiat Oncol Biol Phys. 2021 May;110(1):53\u201367. 10.1016\/j.ijrobp.2020.10.034","DOI":"10.1016\/j.ijrobp.2020.10.034"},{"key":"94617","doi-asserted-by":"crossref","unstructured":"Kennedy WR, DeWees TA, Acharya S, Mahmood M, Knutson NC, Goddu SM, et al. Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery . J Neurosurg. 2020 Dec;135(3):855\u201361. 10.3171\/2020.7.Jns192210 doi: https:\/\/doi.org\/10.3171\/2020.7.JNS192210","DOI":"10.3171\/2020.7.JNS192210"},{"key":"94618","doi-asserted-by":"crossref","unstructured":"Minniti G, D\u2019Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases . J Neurooncol. 2014 Apr;117(2):295\u2013301. 10.1007\/s11060-014-1388-3","DOI":"10.1007\/s11060-014-1388-3"},{"key":"94619","unstructured":"Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, et al.; Japan Clinical Oncology Group. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018 Jun;JCO2018786186(33):JCO2018786186. 10.1200\/JCO.2018.78.6186; Epub ahead of print."},{"key":"94620","doi-asserted-by":"crossref","unstructured":"Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040\u20138. 10.1016\/S1470-2045(17)30414-X","DOI":"10.1016\/S1470-2045(17)30414-X"},{"key":"94621","doi-asserted-by":"crossref","unstructured":"Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb;31(5):616\u201322. 10.1200\/JCO.2012.44.6112","DOI":"10.1200\/JCO.2012.44.6112"},{"key":"94622","doi-asserted-by":"crossref","unstructured":"Chiarion-Sileni V, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015 Jun;33(18 _suppl):LBA1. 10.1200\/jco.2015.33.18_suppl.lba1","DOI":"10.1200\/jco.2015.33.18_suppl.lba1"},{"key":"94623","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, Ribas A, Liszkay G, Maio M, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021 Oct;27(19):5225\u201335. 10.1158\/1078-0432.CCR-21-0809","DOI":"10.1158\/1078-0432.CCR-21-0809"},{"key":"94624","doi-asserted-by":"crossref","unstructured":"Borius PY, R\u00e9gis J, Carpentier A, Kalamarides M, Valery CA, Latorzeff I. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and\/or immunotherapy) in brain metastases: a systematic review. Cancer Metastasis Rev. 2021 Mar;40(1):341\u201354. 10.1007\/s10555-020-09949-9","DOI":"10.1007\/s10555-020-09949-9"},{"key":"94625","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, Gurewitz J, Bernstein K, Kondziolka D, Fakhoury KR, Rusthoven CG, et al. Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients. Neurosurgery. 2022 Dec;91(6):872\u201382. 10.1227\/neu.0000000000002127","DOI":"10.1227\/neu.0000000000002127"},{"key":"94626","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, Kowalchuk RO, Gurewitz J, Bernstein K, Kondziolka D, Niranjan A, et al. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. Int J Radiat Oncol Biol Phys. 2023 Jul;116(4):858\u201368. 10.1016\/j.ijrobp.2023.01.017","DOI":"10.1016\/j.ijrobp.2023.01.017"},{"key":"94627","doi-asserted-by":"crossref","unstructured":"Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990 Feb;322(8):494\u2013500. 10.1056\/NEJM199002223220802","DOI":"10.1056\/NEJM199002223220802"},{"key":"94628","doi-asserted-by":"crossref","unstructured":"Carrubba CJ, Vitaz TW. Factors affecting the outcome after treatment for metastatic melanoma to the brain. Surg Neurol. 2009 Dec;72(6):707\u201311. 10.1016\/j.surneu.2009.03.005","DOI":"10.1016\/j.surneu.2009.03.005"},{"key":"94629","doi-asserted-by":"crossref","unstructured":"Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg. 2011 Jul;115(1):30\u20136. 10.3171\/2011.3.JNS091107","DOI":"10.3171\/2011.3.JNS091107"},{"key":"94630","doi-asserted-by":"crossref","unstructured":"Miller D, Zappala V, El Hindy N, Livingstone E, Schadendorf D, Sure U, et al. Intracerebral metastases of malignant melanoma and their recurrences\u2014a clinical analysis. Clin Neurol Neurosurg. 2013 Sep;115(9):1721\u20138. 10.1016\/j.clineuro.2013.03.019","DOI":"10.1016\/j.clineuro.2013.03.019"},{"key":"94631","doi-asserted-by":"crossref","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004 Apr;22(7):1293\u2013300. 10.1200\/JCO.2004.08.140","DOI":"10.1200\/JCO.2004.08.140"},{"key":"94632","doi-asserted-by":"crossref","unstructured":"Sch\u00f6del P, Schebesch KM, Brawanski A, Proescholdt MA. Surgical resection of brain metastases-impact on neurological outcome. Int J Mol Sci. 2013 Apr;14(5):8708\u201318. 10.3390\/ijms14058708","DOI":"10.3390\/ijms14058708"},{"key":"94633","unstructured":"Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005 May;56(5):1021\u201334."},{"key":"94634","doi-asserted-by":"crossref","unstructured":"Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002 Mar;96(3):552\u20138. 10.3171\/jns.2002.96.3.0552","DOI":"10.3171\/jns.2002.96.3.0552"},{"key":"94635","doi-asserted-by":"crossref","unstructured":"Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020 May;182(5):1148\u201357. 10.1111\/bjd.18524","DOI":"10.1111\/bjd.18524"},{"key":"94636","doi-asserted-by":"crossref","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863\u201373. 10.1016\/S1470-2045(17)30429-1","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"94637","doi-asserted-by":"crossref","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):976\u201383. 10.1016\/S1470-2045(16)30053-5","DOI":"10.1016\/S1470-2045(16)30053-5"},{"key":"94638","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672\u201381. 10.1016\/S1470-2045(18)30139-6","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"94639","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 Dec;22(12):1692\u2013704. 10.1016\/S1470-2045(21)00545-3","DOI":"10.1016\/S1470-2045(21)00545-3"},{"key":"94640","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Qui\u00f1ones-Hinojosa A, Zaorsky NG, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019 Jan;130:104\u201312. 10.1016\/j.radonc.2018.08.025","DOI":"10.1016\/j.radonc.2018.08.025"},{"key":"94641","doi-asserted-by":"crossref","unstructured":"Lu VM, Goyal A, Rovin RA, Lee A, McDonald KL. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol. 2019 Jan;141(1):1\u201312. 10.1007\/s11060-018-03020-y","DOI":"10.1007\/s11060-018-03020-y"},{"key":"94642","doi-asserted-by":"crossref","unstructured":"Petrelli F, De Stefani A, Trevisan F, Parati C, Inno A, Merelli B, et al. Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019 Dec;144:102830. 10.1016\/j.critrevonc.2019.102830","DOI":"10.1016\/j.critrevonc.2019.102830"},{"key":"94643","doi-asserted-by":"crossref","unstructured":"Pin Y, Paix A, Todeschi J, Antoni D, Proust F, No\u00ebl G. Brain metastasis formation and irradiation by stereotactic radiation therapy combined with immunotherapy: A systematic review. Crit Rev Oncol Hematol. 2020 May;149:102923. 10.1016\/j.critrevonc.2020.102923","DOI":"10.1016\/j.critrevonc.2020.102923"},{"key":"94644","doi-asserted-by":"crossref","unstructured":"Bhatia A, Birger M, Veeraraghavan H, Um H, Tixier F, McKenney AS, et al. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro Oncol. 2019 Dec;21(12):1578\u201386. 10.1093\/neuonc\/noz141","DOI":"10.1093\/neuonc\/noz141"},{"key":"94645","doi-asserted-by":"crossref","unstructured":"van Opijnen MP, Dirven L, Coremans IE, Taphoorn MJ, Kapiteijn EH. The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. Int J Cancer. 2020 Mar;146(6):1479\u201389. 10.1002\/ijc.32696","DOI":"10.1002\/ijc.32696"},{"key":"94646","doi-asserted-by":"crossref","unstructured":"Moyers JT, Chong EG, Peng J, Tsai HH, Sufficool D, Shavlik D, et al. Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases. Cancer Med. 2021 Feb;10(4):1201\u201311. 10.1002\/cam4.3716","DOI":"10.1002\/cam4.3716"},{"key":"94647","doi-asserted-by":"crossref","unstructured":"Weaver BD, Goodman JR, Jensen R. Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review. Cureus. 2019 Nov;11(11):e6147. 10.7759\/cureus.6147","DOI":"10.7759\/cureus.6147"},{"key":"94648","doi-asserted-by":"crossref","unstructured":"Rauschenberg R, Bruns J, Br\u00fctting J, Daubner D, Lohaus F, Zimmer L, et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Eur J Cancer. 2019 Mar;110:11\u201320. 10.1016\/j.ejca.2018.12.023","DOI":"10.1016\/j.ejca.2018.12.023"},{"key":"94649","doi-asserted-by":"crossref","unstructured":"Tan XL, Le A, Scherrer E, Tang H, Kiehl N, Han J, et al. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Front Oncol. 2022 Dec;12:1025664. 10.3389\/fonc.2022.1025664","DOI":"10.3389\/fonc.2022.1025664"},{"key":"94650","doi-asserted-by":"crossref","unstructured":"Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, et al. Immunotherapy plus surgery\/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Immunotherapy. 2019 Mar;11(4):297\u2013309. 10.2217\/imt-2018-0149","DOI":"10.2217\/imt-2018-0149"},{"key":"94651","doi-asserted-by":"crossref","unstructured":"Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol. 2018 Aug;128(2):266\u201373. 10.1016\/j.radonc.2018.06.017","DOI":"10.1016\/j.radonc.2018.06.017"},{"key":"94652","doi-asserted-by":"crossref","unstructured":"Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, et al. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and\/or immune-based therapies on treatment outcome. J Neurosurg. 2018 Jul;129(1):50\u20139. 10.3171\/2017.1.JNS162797","DOI":"10.3171\/2017.1.JNS162797"},{"key":"94653","doi-asserted-by":"crossref","unstructured":"Martins F, Schiappacasse L, Levivier M, Tuleasca C, Cuendet MA, Aedo-Lopez V, et al. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study. J Neurooncol. 2020 Jan;146(1):181\u201393. 10.1007\/s11060-019-03363-0","DOI":"10.1007\/s11060-019-03363-0"},{"key":"94654","doi-asserted-by":"crossref","unstructured":"Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mul\u00e9 JJ, et al. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer. 2018 Jan;124(2):297\u2013305. 10.1002\/cncr.30946","DOI":"10.1002\/cncr.30946"},{"key":"94655","doi-asserted-by":"crossref","unstructured":"Ge Y, Che X, Gao X, Zhao S, Su J. Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review. Melanoma Res. 2021 Oct;31(5):413\u201320. 10.1097\/CMR.0000000000000761","DOI":"10.1097\/CMR.0000000000000761"},{"key":"94656","doi-asserted-by":"crossref","unstructured":"Liao G, Fu Y, Arooj S, Khan M, Li X, Yan M, et al. Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. Front Oncol. 2022 Jun;12:704890. 10.3389\/fonc.2022.704890","DOI":"10.3389\/fonc.2022.704890"},{"key":"94657","doi-asserted-by":"crossref","unstructured":"Hassel JC, Schank TE, Smetak H, M\u00fchlbauer J, Salzmann M, Machiraju D, et al. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA). OncoImmunology. 2022 Apr;11(1):2066609. 10.1080\/2162402X.2022.2066609","DOI":"10.1080\/2162402X.2022.2066609"},{"key":"94658","doi-asserted-by":"crossref","unstructured":"Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Apr;29(4):898\u2013905. 10.1038\/s41591-022-02170-x","DOI":"10.1038\/s41591-022-02170-x"},{"key":"94659","doi-asserted-by":"crossref","unstructured":"K. B. Rami A. El Shafie, Karina B\u00f6hm, Dorothea Weber, Kristin Lang, Fabian Schlaich, Sebastian Adeberg,Angela Paul, Matthias F. Haefner, Sonja Katayama, Juliane H\u00f6rner-Rieber,Philipp Hoegen, Sarah L\u00f6w, J\u00fcrgen Debus,J\u00fcrgen Debus, Stefan Rieken, Denise Bernhardt, Palliative Radiotherapy for Leptomeningeal Carcinomatosis\u2013Analysis of Outcome, Prognostic Factors, and Symptom Response, Front. Oncol, vol. Volume 8 - 2018 08 January 2019.","DOI":"10.3389\/fonc.2018.00641"},{"key":"94660","doi-asserted-by":"crossref","unstructured":"Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, et al. Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. J Clin Oncol. 2022 Nov;40(33):3858\u201367. 10.1200\/JCO.22.01148","DOI":"10.1200\/JCO.22.01148"},{"key":"94661","doi-asserted-by":"crossref","unstructured":"Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 Mar;21(3):358\u201372. 10.1016\/S1470-2045(20)30062-0","DOI":"10.1016\/S1470-2045(20)30062-0"},{"key":"94662","doi-asserted-by":"crossref","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance Fernandez AM, Dalle S, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res. 2023 Sep;29(17):3352\u201361. 10.1158\/1078-0432.CCR-22-3145","DOI":"10.1158\/1078-0432.CCR-22-3145"},{"key":"94663","doi-asserted-by":"crossref","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022 Jul;170:236\u201355. 10.1016\/j.ejca.2022.03.008","DOI":"10.1016\/j.ejca.2022.03.008"},{"key":"94664","doi-asserted-by":"crossref","unstructured":"Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, et al. Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial. JAMA Dermatol. 2022 Jan;158(1):33\u201342. 10.1001\/jamadermatol.2021.4704","DOI":"10.1001\/jamadermatol.2021.4704"},{"key":"94665","doi-asserted-by":"crossref","unstructured":"Gassenmaier M, Stec T, Keim U, Leiter U, Eigentler TK, Metzler G, et al. Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):63\u201370. 10.1111\/jdv.15194","DOI":"10.1111\/jdv.15194"},{"key":"94666","unstructured":"Zissimopoulos A, Karpouzis A, Karaitianos I, Baziotis N, Tselios I, Koutis C. [Serum levels of S-100b protein after four years follow-up of patients with melanoma]. Hell J Nucl Med. 2006;9(3):204\u20137."},{"key":"94667","doi-asserted-by":"crossref","unstructured":"Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U; Scottish Melanoma Group. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol. 1999 Feb;140(2):249\u201354. 10.1046\/j.1365-2133.1999.02657.x","DOI":"10.1046\/j.1365-2133.1999.02657.x"},{"key":"94668","unstructured":"Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol. 2013 Sep;6(9):18\u201326."},{"key":"94669","doi-asserted-by":"crossref","unstructured":"Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan;103(2):129\u201342. 10.1093\/jnci\/djq455","DOI":"10.1093\/jnci\/djq455"},{"key":"94670","unstructured":"S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms in German Melanoma AWMF-S3-Guideline 2020: https:\/\/register.awmf.org\/assets\/guidelines\/032-024OLl_S3_Melanom-Diagnostik-Therapie-Nachsorge_2020-08.pdf"},{"key":"94671","doi-asserted-by":"crossref","unstructured":"Riquelme-Mc Loughlin C, Podlipnik S, Bosch-Amate X, Riera-Monroig J, Barreiro A, Espinosa N, et al. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study. J Am Acad Dermatol. 2019 Dec;81(6):1330\u20138. 10.1016\/j.jaad.2019.05.076","DOI":"10.1016\/j.jaad.2019.05.076"},{"key":"94672","doi-asserted-by":"crossref","unstructured":"Deichmann M, Benner A, Bock M, J\u00e4ckel A, Uhl K, Waldmann V, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999 Jun;17(6):1891\u20136. 10.1200\/JCO.1999.17.6.1891","DOI":"10.1200\/JCO.1999.17.6.1891"},{"key":"94673","doi-asserted-by":"crossref","unstructured":"Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology. 2006;213(3):187\u201391. 10.1159\/000095034","DOI":"10.1159\/000095034"},{"key":"94674","doi-asserted-by":"crossref","unstructured":"Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma . Eur J Cancer. 2012 Mar;48(5):695\u2013702. 10.1016\/j.ejca.2011.08.007","DOI":"10.1016\/j.ejca.2011.08.007"},{"key":"94675","doi-asserted-by":"crossref","unstructured":"Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges. 2016 Feb;14(2):158\u201364. 10.1111\/ddg.12727","DOI":"10.1111\/ddg.12727"},{"key":"94676","doi-asserted-by":"crossref","unstructured":"Pikturniene R, Cesas A, Jarmalaite S, Razbadauskas A, Urbonas V. Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions. Cancers (Basel). 2024 Mar;16(6):1197. 10.3390\/cancers16061197","DOI":"10.3390\/cancers16061197"},{"key":"94677","doi-asserted-by":"crossref","unstructured":"Long GV, Ascierto PA, Guo J, Chandra S, Tarhini AA, Mu\u00f1oz E, et al. Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III\u2013IV melanoma: primary results from RELATIVITY-098 [Meeting Abstract: 2025 ASCO Annual Meeting II]. J Clin Oncol. 2025;43(17 suppl.): 10.1200\/JCO.2025.43.17_suppl.LBA9500","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9500"}],"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/4210\/6304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/4210\/6305","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/4210\/6304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:30:42Z","timestamp":1752751842000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/4210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":194,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.57187\/s.4210","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}